Centessa Pharmaceuticals plc
CNTA
주식 순위
#2960
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical... Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
주가
$40.50
마지막 동기화: 2026-06-29
시가총액
$6.22B
변동 (1일)
0.00%
변동 (1년)
77.71%
국가
GB
거래 Centessa Pharmaceuticals plc (CNTA)
카테고리
Healthcare
Centessa Pharmaceuticals plc (CNTA)의 P/E 비율
October 2026 기준 P/E 비율 TTM: -22.75
Centessa Pharmaceuticals plc의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 -22.75입니다. 2023년 말 기준 P/E 비율은 -5.07였습니다.
Centessa Pharmaceuticals plc의 P/E 비율 기록 (2019 ~ 2026)
매년 말 P/E 비율
| 연도 | P/E 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | -22.75 | 179.86% |
| 2024 | -8.13 | 60.50% |
| 2023 | -5.07 | 278.38% |
| 2022 | -1.34 | -98.59% |
| 2021 | -95.03 | -34.28% |
| 2020 | -144.60 | -67.01% |
| 2019 | -438.27 | 0.00% |
유사 기업 또는 경쟁사의 P/E 비율
| 회사 | P/E 비율 | P/E 비율 차이 | 국가 |
|---|---|---|---|
| 28.78 | -226.50% |
US
|
|
| -28.36 | 24.64% |
US
|
|
| -24.57 | 7.97% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -233.30% |
NL
|
P/E 비율 읽는 방법
P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.
P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.
양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.